What happened to the CSL (ASX:CSL) share price in October?

How did CSL shares perform last month? We take a closer look

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price kicked up a notch in October, nearing its 52-week high of $320.42. While the global biotech didn't release any market-sensitive news, investors appeared to be buying the company's shares.

They gained around 4% during October to end the month at $300.49.

At the time of writing, the CSL share price is $310.93, up 0.03% on the day. This means its shares are around 3% off breaking a new 52-week high and are up around 8% over the last month.

How did CSL fare last month?

During early October, CSL released the commentary around its annual general meeting (AGM).

Almost all of the information had already been divulged in previous market updates such as its full-year results in August. However, it didn't stop investors pushing up the CSL share price on the day to $292.68, a gain of 1.80%.

The surge came despite the S&P/ASX 200 Index (ASX: XJO) falling 0.26% to 7,280 points on the day.

CSL noted that it sees the current FY22 financial year as a transitional one. The board is confident the company can return to sustainable growth in the next 24 months. It has several major expansion projects underway along with developing its R&D pipeline products.

Nonetheless, there is still a strong demand for its portfolio of therapies and vaccines, which have offset plasma collection headwinds.

Plasma levels for FY21 were down about 20% on the previous year and these were collected at a higher cost per litre. This came from additional PPE and cleaning requirements, social distancing and labour costs as well as higher compensation paid to donors.

Most recently, a couple of brokers rated the company's shares following CSL's annual R&D day.

Multinational investment firm Goldman Sachs raised its price target by 1% to $305.00, while Jefferies had a more bullish outlook. The latter lifted its 12-month view by 3.1% to $338.00. Based on the current share price, this implies an upside of around 9% on Jefferies' assessment.

CSL share price review

When looking over the last 12 months, the CSL share price has gained around 6%. Year-to-date it has fared slightly better, up almost 10% for the period.

CSL presides a market capitalisation of roughly $141.49 billion, and has approximately 455.67 million shares on issue.

Should you invest $1,000 in Aristocrat Leisure Limited right now?

Before you buy Aristocrat Leisure Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Aristocrat Leisure Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »